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et al4 attempted to identify additional predictors 
allowing to evaluate embolic risk in this setting.
Transthoracic echocardiography (TTE) has a 
very low sensitivity in identifying LAAT but pro-
vides information on cardiac structure and func-
tion, which helps assess the embolic risk.3-8 Nev-
ertheless, TTE-derived parameters (ie, ejection 
fraction [EF] <40%) play only a minor role in the 
current risk classification scheme. The present-
ed study identifies left ventricular (LV) and left 
atrial size (LV end-diastolic dimension [LVEDd] 
>52 mm; left atrial diameter >51mm) as inde-
pendent predictors of the LAA thrombogenic mi-
lieu. The calculated cut-off value for the LVEDd is 
puzzling, as 52 mm is within the normal range.9 
The chamber size and volume indexation to the 
body surface area may better predict LAAT, but 
this was not analyzed in the study group.10 A re-
duced EF (being also a part of the CHA2DS2-VASc 
score) was associated with LAAT in a univariate 
but not in a multivariate analysis. It should be 
mentioned, however, that the Teicholz’s formula 
used in the study is currently not recommended, 
and a more precise Simpson’s method should be 
used instead.5,8 The authors did not analyze the 
LV mass index or LV diastolic function, although 
some studies suggested a discriminative capabili-
ty of such parameters in the prediction of LAAT.11
TEE is a very useful tool for excluding LAAT 
before cardioversion.3 In the Stroke Prevention 
in Atrial Fibrillation (SPAF) substudy, the pres-
ence of LAAT, LAA peak flow velocity of less than 
27 cm/s, and aortic plaque were all independent-
ly associated with thromboembolic events.12 In 
the current era, when left atrial occluders have 
become available, more focus has been placed on 
LAA imaging, and important limitations of LAA 
evaluation on TEE were documented compared 
with computed tomography, magnetic resonance 
imaging, and contrast angiography. In less experi-
enced hands, TEE may provide both false-positive 
Atrial fibrillation (AF) is the most common sus-
tained arrhythmia. It occurrs in up to 2% of the 
general population, particularly in elderly pa-
tients, and remains the major challenge in car-
diology.1 AF is associated with increased risk of 
thromboembolic events, frequently leading to 
large strokes.1-3 Decision making for thrombo-
prophylaxis needs to balance the risk of stroke 
against the risk of major bleeding.2 Stroke risk is 
a continuum but current guidelines recommend 
focusing on the identification of “truly low-risk“ 
patients with AF, in whom anticoagulation could 
be safely avoided.2,4,5  
The CHA2DS2-VASc score is related to long-term 
risk of ischemic stroke in patients with nonvalvu-
lar AF and not receiving anticoagulation. The score 
is based on simple clinical parameters, not taking 
into account anatomic data available from cardi-
ac imaging studies. Nevertheless, the CHA2DS2-
VASc score has been well validated and became 
the most common tool used for the assessment 
of long-term stroke risk in clinical practice.4 
AF predisposes to blood stasis and may lead to 
atrial thrombus formation.3 In up to 90% of cas-
es, it is located in the left atrial appendage (LAA) 
and can be mobilized when the sinus rhythm is re-
stored. However, there is no validated scoring sys-
tem assessing the risk of thromboembolic compli-
cations of cardioversion. The recommended way to 
avoid stroke is not to perform cardioversion if AF 
persists for more than 48 hours and if there had 
been no previous anticoagulant treatment lasting 
at least 3 to 4 weeks.1,6 The number of such patients 
is substantial, and in clinical practice, they are ei-
ther discharged home with an anticoagulant pre-
scribed or require transesophageal echocardiogra-
phy (TEE) to exclude LAA thrombus (LAAT). It is 
clear that such an approach causes delays and gen-
erates costs and logistic problems, and a delay in 
cardioversion may decrease the number of success-
ful cardioversion procedures. This is why, Jaroch 
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The presented study found that a long history 
of AF (>1 year) and aortic calcification (but not 
the history of vascular disease) were also predic-
tors of LAAT.
The presented work contributes to the ongoing 
discussion about the risk stratification and opti-
mal management of patients with AF. It confirms 
the fact that the CHA2DS2-VASc score is not suited 
for the prediction of LAAT before cardioversion. 
New methods combining clinical and echocardio-
graphic findings would be very useful in this clin-
ical scenario. The study suggests that the enlarged 
left ventricle and left atrium as well as a long his-
tory of AF and the presence of aortic calcifications 
may be considered risk factors for the formation 
of LAAT. The CATES score proposes an alternative 
method for precardioversion assessment. Howev-
er, all these findings still need further validation 
in large population samples to confirm its capabil-
ity of selecting a very low-risk group of patients 
that can be spared TEE. In the meantime, the ex-
isting AF strategies and guidelines remain valid.
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(caused by reverberations) and false-negative re-
sults (related to a complex LAA anatomy). TEE 
can detect LAAT, which precludes cardioversion, 
but on the other hand, if LAAT is not visualized 
on TEE, it does not mean that thromboembolic 
complications of cardioversion may be complete-
ly excluded. The LAA morphology may be very 
complex, with several curved, trabeculated, and 
poorly visible lobes. Another reason for embolic 
complications that cannot be predicted by TEE is 
the prolonged LAA stunning, which occurs after 
cardioversion and causes delayed clot formation.
It should be noted that Jaroch et al4 described 
the correct TEE method for LAA scanning. They ob-
tained not only the 2 perpendicular LAA views used 
to position the imaging plane well so as to avoid re-
verberations, but also performed continuous 0° to 
180°-plane sweep to look at the LAA structure from 
all possible dimensions.13 They could not use 3-di-
mensional echocardiography, which may be very 
helpful in difficult cases. Of note, they had to ex-
clude a number of patients in whom 2 experts did 
not reach consensus about the presence of LAAT. 
There are several other TEE factors not analyzed 
in the present study, for example, the anatomical 
type of the LAA. Patients with “chicken--wing” 
LAA morphology are less likely to have an embol-
ic event compared with those with 2 other types 
of morphology. Moreover, emptying velocities re-
flect the mechanical function of the LAA, and low 
LAA velocities (<20 cm/s) correlate with the pres-
ence of spontaneous echo contrast and thrombus 
formation.14 Currently, several new methods for 
the evaluation of LAA function (LAA EF, wall de-
formation) are under evaluation.
The CHA2DS2-VASc score calculated in the 
study group did not discriminate the presence 
of LAAT. Even in patients with a CHA2DS2-VASc 
score of 0, spontaneous echo contrast was found. 
Among patients with a CHA2DS2-VASc score of 1, 
almost 19% had an LAAT identified. Important-
ly, this scale was developed to assess the risk of 
stroke (not LAAT), in patients not receiving an-
ticoagulation. In the study group, more than half 
of the patients received some (probably not ad-
equate) anticoagulation. It may have influenced 
LAAT.4,5 Recent studies have shown low-to-moder-
ate usefulness of the CHADS2 and CHA2DS2-VASc 
scores to predict the presence of LAAT and failed 
to identify precisely the very low-risk group.15
The number of cardioversion candidates is large 
and it is not reasonable to perform a semi-inva-
sive TEE study in all of them. Not only the num-
ber of TEE probes but also the number of echocar-
diographers experienced in the precise evaluation 
of the LAA is limited, and false results may lead to 
errors.1,2 The Cardioversion Safety Score (CATES) 
has been recently proposed to detect patients with 
very low risk for thromboembolism who can be 
spared TEE.16 The score includes C-reactive pro-
tein levels, indexed atrial volume, troponin, AF 
duration, and history of embolism. It was evalu-
ated in a relatively small group of 180 patients.16
